CLXT News and Press, Calyxt Inc. From 01/17/23

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Bukhta Yurii / Shutterstock.com Viveve Medical (NASDAQ: VIVE ) stock is falling hard on Tuesday after releasing results from the company’s latest clinical trial. That trial covers the use of the Viv...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: oneinchpunch/Shutterstock.com We’re starting off Tuesday with a look at the biggest pre-market stock movers traders will want to keep an eye on! Moving stocks this morning are merger plans, clinical trial...

NEW YORK, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company using its gene editing platform to deliver life-saving cell and gene therapies, announced today that Cibus Global LLC, a Delaware limited liability company (ȁ...

The shares of plant-based synthetic biology company Calyxt, Inc. ( NASDAQ: CLXT ) climbed ~88% pre-market Tuesday after announcing a merger agreement with Cibus, an agricultural technology company focused on plant-based gene editing. "Cibus is an excellent strategic fit for Calyxt...

Calyxt and Cibus Announce Definitive Merger Agreement to Create Industry-Leading Precision Gene Editing and Trait Licensing Company PR Newswire – The merger will bring together the technology platforms and facilities of two pioneering companies to create a leader in...

Calyxt Achieves Phase 1 Milestone in Collaboration Agreement to Develop Alternative to Palm Oil PR Newswire ROSEVILLE, Minn. , Nov. 18, 2022 /PRNewswire/ -- Calyxt, Inc. (NASDAQ: CLXT), a plant-based synthetic biology company announced today that it ...

Calyxt Granted 180-Day Extension by Nasdaq to Regain Compliance with Bid Price Rule PR Newswire ROSEVILLE, Minn. , Nov. 17, 2022 /PRNewswire/ -- Calyxt, Inc (Nasdaq: CLXT) a plant-based synthetic biology focused on engineering sustainable ingredients for ...

Calyxt, Inc. (CLXT) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants William Koschak - CFO Michael Carr - President and CEO Presentation Operator Good afternoon, ladies and gentlemen, and thank you for standing by....

Calyxt press release ( NASDAQ: CLXT ): Q3 Non-GAAP EPS of -$0.13 beats by $0.02 . Revenue of $0.04M (-99.5% Y/Y) misses by $0.31M . "We continue to be focused on the effective and prudent use of our cash resources and we have reduced costs while executing on ne...

Calyxt Reports Third Quarter 2022 Financial Results and Provides Corporate Update PR Newswire — Successfully produced squalene, an important ingredient for personal care products and vaccine adjuvants— — Continued to progress custom...